LONDON (ShareCast) - (Sharecast News) - Anti-microbial technology company Byotrol expects to report an EBITDA loss from its last trading year as a result of delayed regulatory approval and higher costs in the US.
Byotrol said on Thursday that it expects to report consolidated full-year revenues of around £4.2m, in line with market expectations, but still anticipates an EBITDA loss of roughly £450,000.

Despite the delayed regulatory approval, which the group has since received, and higher marketing and research costs in the US, Byotrol told investors it had continued to make "good progress in the US", leaving its board confident that its slightly increased investment was merited.

The AIM-listed company's cash balance fell 18.5% to £2.85m following its acquisition of Medimark Scientific in August.

Chief executive David Traynor said: "Byotrol is continuing to progress well and all key strategic initiatives are performing to plan. We are very excited about the potential for the enlarged business including MSL and for the synergies that will be released from the combination in due course."

At 0945 BST, Byotrol shares were down 3.36% to 2.30p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE